Showing 1–16 of 19 resultsSorted by popularity
Long-acting GLP-1 receptor agonist for appetite regulation and metabolic research. Investigate weight management pathways.
Semaglutide is a long-acting GLP-1 receptor agonist featuring Aib substitution and fatty acid bioconjugation for DPP-4 resistance and a 7-day half-life. It stimulates glucose-dependent insulin secretion, suppresses glucagon release, and centrally modulates hypothalamic satiety pathways for strong appetite reduction.
Tirzepatide is a pioneering, synthetically engineered 39-amino acid peptide that functions as a dual agonist. >99% purity confirmed by HPLC analysis.
Tirzepatide is a peptide that activates both GLP-1 and GIP receptors. It was developed to fight type 2 diabetes by lowering blood sugar levels, boosting insulin sensitivity, and reducing hunger. In addition to cardiovascular benefits, recent trials have demonstrated impressive results when used for weight loss.
Tirzepatide is a peptide that activates both GLP-1 and GIP receptors. It was developed to fight type 2 diabetes by lowering blood sugar levels, boosting insulin sensitivity, and reducing hunger. In addition to cardiovascular benefits, recent trials have demonstrated impressive results when used for weight loss.
Tirzepatide exerts its physiological influence by simultaneously activating the GLP-1 and GIP receptors. >99% purity confirmed by HPLC analysis.
Min order >20 kits price low to $190/kit
Min order >20 kits price low to $130/kit
Min order >20 kits price low to $110/kit
Min order >20 kits price low to $90/kit
Min order >20 kits price low to $135/kit
Min order >20 kits price low to $70/kit
Cagrilintide is a long-acting synthetic analog of the endogenous pancreatic hormone amylin.
Cagrilintide is a long-acting synthetic amylin analog that crosses the blood-brain barrier to activate amylin and calcitonin receptors in the area postrema, suppressing appetite and delaying gastric emptying. Its 170-hour half-life enables once-weekly research protocols.
Semaglutide is a long-acting GLP-1 receptor agonist featuring Aib substitution and fatty acid bioconjugation for DPP-4 resistance and a 7-day half-life. It stimulates glucose-dependent insulin secretion, suppresses glucagon release, and centrally modulates hypothalamic satiety pathways for substantial appetite reduction.
Tirzepatide is a pioneering, synthetically engineered 39-amino acid peptide that functions as a dual agonist.
End of content
End of content
No products in the cart.
